Abstract 72P
Background
Ado-trastuzumab emtansine (T-DM1) became the first FDA approved antibody-drug conjugate in breast cancer. This real-world study aimed to evaluate the efficacy and safety of first approved T-DM1 biosimilar (ZRC-3256) in India for HER2-positive breast cancer in routine practice.
Methods
It was a retrospective, single-center, observational study and included patients treated between May 2021 to December 2022. Eligible patients were all female with HER2-positive metastatic breast cancer treated with trastuzumab and taxane prior and at progression treated with standard dose T-DM1 biosimilar. Brain metastasis patients treated with appropriate local therapy were allowed. The primary endpoint includes response rate and progression-free survival (PFS). The secondary endpoints were time to treatment failure (TTF), safety and overall survival (OS). Descriptive statistics were used to recapitulate the patient and other related characteristics. The study was approved by the institute ethics committee.
Results
30 patients treated with T-DM1 biosimilar were included. 5 among them had brain involvement. Median age was 57 years, all had received prior HER2-targeted therapy (100%) and majority of patients (86.67%) were post-menopausal. 83.3% patients received T-DM1 therapy in 2nd line and the complete response rate was 66.63%. Median progression free survival and time to treatment failure were found to be around 13.5 months (95% CI: 13.46 – 17.17) and 13 months (95% CI: 11.47 – 14.53) respectively. Median overall survival data is yet to mature and stand at 24 months (95% CI: 21.03 – 26.97) with limited events. Common adverse events were elevated transaminases, anemia, and thrombocytopenia, with most being manageable and reversible. 10% patients experienced adverse events of Grade 3 or above.
Conclusions
The study findings suggested that T-DM1 is effective in managing HER2-positive metastatic breast cancer and the outcomes with T-DM1 biosimilar usage in the real world are consistent with the published evidence of randomized controlled clinical trials with T-DM1. So, this biosimilar can be a reasonable option in routine clinical practice in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract